We are committed to partnering with you to support all affected patients. We have continued to make progress on the remediation of CPAP and BiPAP devices and are asking customers and clinicians to help us to remind patients that they may need to take a specific action in the Patient Portal to receive their replacement device.
Options for your CPAP and BiPAP patients If your CPAP or BiPAP patients have not yet received a replacement device, it may be because we need further information or, in some cases, consent from them. Please encourage them to visit the Patient Portal to learn more and determine if they need to take additional action. Some patients may have the option to choose a replacement device with Auto-adjusting CPAP settings if we have been unable to obtain their updated prescription settings. Eligible patients will be contacted directly by Philips Respironics and will also see this option available when they log into the Patient Portal. Learn more about Auto-adjusting CPAP options for your patients here.
While we've made progress with CPAP and BiPAP devices, we remain on a separate remediation timeline for ventilation devices. Please visit our ventilation news and updates page for the latest information.
We are transforming our processes and the way we operate so we can deliver what matters most to our patients – safe and effective therapy.”
David Ferguson
David Ferguson, Business Leader, Sleep & Respiratory Care, joined Philips in March 2021. Since then, he has led the organization through the voluntary medical device recall of certain CPAP, BiPAP and Mechanical Ventilator devices. With the comprehensive test and research program for affected CPAP/BiPAP sleep therapy devices† now complete, we asked him about what’s changed since the start of the recall, what the test results mean for patients, and what to expect from Philips Respironics in the future.
† First-generation DreamStation, System One and DreamStation Go devices
Philips Respironics completed the analyses for System One and DreamStation Go sleep therapy devices indicating that the volatile organic compounds (VOCs) and the particulate matter (PM) emissions related to foam degradation are within the appliable safety limits. Additional visual assessments have been performed and confirm the low prevalence of significant foam degradation.
You are about to visit a Philips global content page
Continue